USSN: 10/317,126 0212-CIP-9

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Beeley et al.

Appln. No.: 1

10/629,649

Filed:

30 July 2003

For:

METHODS AND COMPOSITIONS

FOR TREATING POLYCYSTIC

OVARY SYNDROME

Art Unit:

1654

Examiner:

RUSSEL, Jeffrey D.

Atty. Docket:

236/097 US-UTL

Confirm. No.:

7870

Box Issue Fee

Commissioner for Patents Washington, D.C. 20231

### FACSIMILE TRANSMITTAL COVER SHEET

# Certificate of Transmission Under 37 C.F.R. 1.8

The following documents are being submitted via facsimile transmittal in response to the Notice of Allowance and Fee(s) Due, mailed April 14, 2006:

Documents(s)		No. of Pages
Part B - Fee(s) Transmittal		1
Loss of Small Entity Status		1
Facsimile Cover Sheet		1
	Total Pages	3

Should any other fee become due or credit become payable during the pendency of these proceedings, the Commissioner is authorized to charge or credit the same to Deposit Account Number 010535.

I hereby certify that the following listed correspondence in the above-referenced application is being transmitted by facsimile to the Commissioner for Patents, Alexandria, VA to telephone number to telephone number (571) 273-2885 on this 10<sup>th</sup> of July, 2006.

Kelly B. Colomon



USSN: 10/629,649 Attorncy Docket No.: 0212-CIP-9

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In rc Application of:

Beeley et al.

Appln. No.: 10/629,649

Filed:

30 July 2003

For:

METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC

OVARY SYNDROME

Art Unit:

1654

Examiner:

RUSSEL, Jeffrey D.

Atty. Docket:

236/097 US-UTL

Confirm. No.:

o.: 7870

#### NOTIFICATION OF LOSS OF SMALL ENTITY STATUS

Box Issue Fee Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 CFR 1.27(g)(2), the undersigned hereby notifies the U.S. Patent and Trademark Office of loss of entitlement to small entity status. This notification is being submitted at the time of paying the earliest of an issue fee or a maintenance fee due after the date on which status as a small entity, as defined in 37 CFR 1.27(a), is no longer appropriate. This notification is signed by an appropriate party, as identified in 37 CFR 1.33(b).

The undersigned believes that the appropriate fee is enclosed or authorization has been given to charge the deposit account. However, in the event any additional fees are due or any amount is to be credited, the undersigned authorizes the Commissioner of Patents to debit or credit Deposit Account No. 010535.

Respectfully Submitted on behalf of Beeley et al.,

10 July 2006

Dated

Susan J. Myers Fitch, Ph.D.

Reg. No. 55,477

AMYLIN PHARMACEUTICAL, INC. 9360 Town Centre Drive

San Diego, CA 92121 Telephone: 858.552.2200

Facsimile: 858.552.2200